Radiopharm Theranostics Ltd (RADX) 뉴스

Lantheus Increases to 12.16% shareholding in Radiopharm with US$5m (A$8m) Placement

Private placement to radiopharmaceutical industry leader Lantheus, for US$5.0 millionPlacement at A$0.060 per...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Radiopharm Announces Strategic Co-Development Partnership with Lantheus for Australia

RAD to advance the clinical development of Lantheus innovative radiopharmaceuticals in Australia Initial...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

RAD 202 Receives Approval to Start Phase 1 Therapeutic Trial

Ethics approval received in Australia for the initiation of RAD’s Phase 1 therapeutic trial of 177Lu-RAD202 in...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form EFFECT - Notice of Effectiveness

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form F-1 - Registration statement for certain foreign private issuers

Radiopharm Achieves Nasdaq Listing of American Depositary Shares

Trading under ticker symbol RADXComplements existing US shareholders (currently holding 21% of Radiopharm)No...